A practical guide for the assay-dependent characterisation of irreversible inhibitors†

IF 3.597 Q2 Pharmacology, Toxicology and Pharmaceutics MedChemComm Pub Date : 2024-11-01 DOI:10.1039/D4MD00707G
Lavleen K. Mader, Jessica E. Borean and Jeffrey W. Keillor
{"title":"A practical guide for the assay-dependent characterisation of irreversible inhibitors†","authors":"Lavleen K. Mader, Jessica E. Borean and Jeffrey W. Keillor","doi":"10.1039/D4MD00707G","DOIUrl":null,"url":null,"abstract":"<p >Irreversible targeted covalent inhibitors, in the past regarded as inappropriately reactive and toxic, have seen a recent resurgence in clinical interest. This paradigm shift is attributed to the exploitation of the two-step mechanism, in which a high affinity and selectivity (<em>i.e.</em>, low <em>K</em><small><sub>I</sub></small>) scaffold binds the target and only then does a pendant low intrinsic reactivity warhead react with the target (moderate <em>k</em><small><sub>inact</sub></small>). This highlights the importance of evaluating inhibitors by deriving both their <em>K</em><small><sub>I</sub></small> and <em>k</em><small><sub>inact</sub></small> values. The development of methods to evaluate these inhibitors by accounting for their time-dependent nature has been crucial to the discovery of promising clinical candidates. Herein, we report all the practical kinetic methods available to date to derive <em>k</em><small><sub>inact</sub></small> and <em>K</em><small><sub>I</sub></small> values. These methods include direct observation of covalent modification, continuous assay (Kitz &amp; Wilson) evaluation, and discontinuous incubation and pre-incubation time-dependent IC<small><sub>50</sub></small> assays. We also provide practical guidelines and examples for performing these assays, comparison of their utility, and perspectives for their extended applications. This review aims to provide clarity about the use of these methods for reporting complete inhibitor kinetic profiles, guiding irreversible drug development towards increased target affinity and selectivity, while modulating <em>in vivo</em> stability and on-target reactivity.</p>","PeriodicalId":88,"journal":{"name":"MedChemComm","volume":" 1","pages":" 63-76"},"PeriodicalIF":3.5970,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"MedChemComm","FirstCategoryId":"1085","ListUrlMain":"https://pubs.rsc.org/en/content/articlelanding/2025/md/d4md00707g","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"Pharmacology, Toxicology and Pharmaceutics","Score":null,"Total":0}
引用次数: 0

Abstract

Irreversible targeted covalent inhibitors, in the past regarded as inappropriately reactive and toxic, have seen a recent resurgence in clinical interest. This paradigm shift is attributed to the exploitation of the two-step mechanism, in which a high affinity and selectivity (i.e., low KI) scaffold binds the target and only then does a pendant low intrinsic reactivity warhead react with the target (moderate kinact). This highlights the importance of evaluating inhibitors by deriving both their KI and kinact values. The development of methods to evaluate these inhibitors by accounting for their time-dependent nature has been crucial to the discovery of promising clinical candidates. Herein, we report all the practical kinetic methods available to date to derive kinact and KI values. These methods include direct observation of covalent modification, continuous assay (Kitz & Wilson) evaluation, and discontinuous incubation and pre-incubation time-dependent IC50 assays. We also provide practical guidelines and examples for performing these assays, comparison of their utility, and perspectives for their extended applications. This review aims to provide clarity about the use of these methods for reporting complete inhibitor kinetic profiles, guiding irreversible drug development towards increased target affinity and selectivity, while modulating in vivo stability and on-target reactivity.

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
不可逆抑制剂特性测定实用指南。
不可逆的靶向共价抑制剂过去被认为具有不适当的反应性和毒性,但最近在临床上再次受到关注。这种模式的转变归功于对两步机制的利用,即高亲和性和选择性(即低 K I)支架与靶点结合,然后低内在反应性的悬垂弹头才与靶点反应(中等 K inact)。这就突出了通过推导 K I 和 k inact 值来评估抑制剂的重要性。考虑到这些抑制剂的时间依赖性,开发评估这些抑制剂的方法对于发现有前景的临床候选药物至关重要。在此,我们报告了迄今为止可用于推导 K inact 和 K I 值的所有实用动力学方法。这些方法包括直接观察共价修饰、连续测定(Kitz & Wilson)评估以及非连续孵育和预孵育时间依赖性 IC50 测定。我们还提供了进行这些测定的实用指南和示例,比较了它们的效用,并展望了它们的扩展应用。本综述旨在阐明如何使用这些方法报告完整的抑制剂动力学曲线,指导不可逆药物开发,以提高靶点亲和力和选择性,同时调节体内稳定性和靶点反应性。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
MedChemComm
MedChemComm BIOCHEMISTRY & MOLECULAR BIOLOGY-CHEMISTRY, MEDICINAL
CiteScore
4.70
自引率
0.00%
发文量
0
审稿时长
2.2 months
期刊介绍: Research and review articles in medicinal chemistry and related drug discovery science; the official journal of the European Federation for Medicinal Chemistry. In 2020, MedChemComm will change its name to RSC Medicinal Chemistry. Issue 12, 2019 will be the last issue as MedChemComm.
期刊最新文献
Back cover Back cover Back cover A practical guide for the assay-dependent characterisation of irreversible inhibitors† Development, biological evaluation, and molecular modelling of some benzene-sulfonamide derivatives as protein tyrosine phosphatase-1B inhibitors for managing diabetes mellitus and associated metabolic disorders†
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1